Molecular Diagnostic Services
Oncology
CommercialActive
Key Facts
About Genloxa
Genloxa is a private, revenue-generating diagnostics laboratory focused on personalized medicine in gastroenterology and oncology. Its core offerings include proprietary 'G-tests' for fecal biomarkers (calprotectin, pancreatic elastase) and the Dose5-FU test, the only service in Poland for monitoring 5-fluorouracil levels during chemotherapy to personalize dosing. The company targets both individual patients and institutional clients like hospitals, leveraging EU-funded R&D projects to expand its test menu and laboratory capabilities. Its strategy centers on providing rapid, non-invasive diagnostics to accelerate treatment decisions and improve therapeutic outcomes.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |